Once-weekly semaglutide 7.2 mg achieved superior weight reduction over the approved 2.4 mg dose and placebo in adults with obesity without diabetes.
Participants receiving the higher dose experienced mean bodyweight reductions of 18.7% at 72 weeks versus 15.6% with 2.4 mg and 3.9% with placebo.
The 7.2 mg dose was associated with significantly higher proportions of participants attaining clinically meaningful weight loss thresholds (up to ≥25%).
The safety profile of semaglutide 7.2 mg retained overall tolerability, with gastrointestinal events being the most common adverse effects.
